drugset
drugset / Trial / NCT07078695

A Trial of SHR-1139 in Healthy Volunteers

NCT07078695 ↗

Phase 1 Active not recruiting 24 enrolled Atridia Pty Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers

Timeline

Start
2025-08-19
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1139 Unknown — Subcutaneous

Indications

psoriasis